US Airways Is on a ...
Health Care: Drugs
Synthetic Biologics Inc (SYN: AMEX)
$1.42 -0.02 | -1.39%
05/21/13 - 03:44 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 0.00 | 3.16M | 103.09K |
| Cost of Sales | 0.00 | 0.00 | 108.92K | -382.09K |
| Gross Operating Profit | 0.00 | 0.00 | 3.06M | 485.18K |
| Selling, General, and Administrative Expenses | 5.01M | 2.59M | 2.70M | 2.58M |
| Research & Development | 12.29M | 3.34M | 1.58M | 1.20M |
| Operating Income before D & A (EBITDA) | -17.30M | -5.93M | -1.23M | -3.30M |
| Depreciation & Amortization | 63.00K | 201.00K | 358.71K | 382.09K |
| Interest Income | 33.00K | 14.00K | 413.00 | 2.96K |
| Other Income - Net | -18.00K | -1.71M | -117.51K | -43.01K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -17.35M | -7.83M | -1.70M | -3.72M |
| Interest Expense | 0.00 | 0.00 | 10.11K | 9.88K |
| Pre-Tax Income | -17.35M | -7.83M | -1.71M | -3.73M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -17.28M | -7.63M | -1.71M | -3.73M |
| Net Income From Discontinued Operations | 216.00K | -523.00K | 0.00 | 0.00 |
| Net Income From Total Operations | -17.07M | -8.15M | -1.71M | -3.73M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -17.07M | -8.15M | -1.71M | -3.73M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-17.28M | -7.63M | -1.71M | -3.73M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -17.28M | -7.63M | -1.71M | -3.73M |
| Basic EPS from Continuing Ops. | -0.50 | -0.27 | -0.08 | -0.18 |
| Basic EPS from Discontinued Ops. | 0.01 | -0.02 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.49 | -0.29 | -0.08 | -0.18 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.49 | -0.29 | -0.08 | -0.18 |
| Basic Normalized Net Income/Share | -0.50 | -0.27 | -0.08 | -0.18 |
| EPS fr Continuing Ops. | -0.50 | -0.27 | -0.08 | -0.18 |
| EPS fr Discontinued Ops | 0.01 | -0.02 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.49 | -0.29 | -0.08 | -0.18 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.49 | -0.29 | -0.08 | -0.18 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.50 | -0.27 | -0.08 | -0.18 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with SYN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest SYN Headlines from TheStreet
- 3 Biotech Stocks Under $5 Moving Higher 02.07.13 | 02:02 pm
- 5 Stocks Poised for Breakouts 07.13.12 | 12:07 pm
- Synovus To Raise $350M in Stock Offer 09.14.09 | 11:09 pm
- Regions' Profit Stung by Fla. Real Estate 07.22.08 | 11:07 am
- Stock Upgrades, Downgrades from TheStreet.com Ratings 11.21.07 | 01:11 pm
- Cramer's 'Mad Money Lightning Round': Best BuyBuyBuy 10.01.07 | 07:10 pm
- Neurocrine Says Sleeping Pill Data Are Good 11.14.02 | 09:11 am
Press Releases for SYN
- Synthetic Biologics To Present At The 2nd Annual Marcum LLP MicroCap Conference - PR Newswire 05.21.13 | 07:05 am
- Synthetic Biologics Reiterates That The Infectious Disease Collaboration With Intrexon Remains In Effect - PR Newswire 04.19.13 | 07:04 pm
- Synthetic Biologics Announces Issuance Of U.S. Patent Covering Combination Of Estriol And Copaxone® For Multiple Sclerosis - PR Newswire 04.04.13 | 01:04 pm
- Synthetic Biologics To Present At The 25th Annual ROTH Conference - PR Newswire 03.12.13 | 07:03 am
- Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board - PR Newswire 02.26.13 | 07:02 am
- Synthetic Biologics Reports That Flupirtine Sublicensee, Meda AB, To Initiate Phase II Fibromyalgia Clinical Trial In U.S. - PR Newswire 02.22.13 | 07:02 am
- Synthetic Biologics To Present At The 2013 BIO CEO & Investor Conference - PR Newswire 02.05.13 | 07:02 am
- Synthetic Biologics To Present At OneMedForum San Francisco 2013 - PR Newswire 01.07.13 | 07:01 am
- Synthetic Biologics And Intrexon Corporation Initiate Development Of Monoclonal Antibodies For Whooping Cough (Pertussis) - PR Newswire 12.20.12 | 04:12 pm
- Synthetic Biologics Closes Deal For Acquisition Of C. Difficile Infectious Disease Program - PR Newswire 12.03.12 | 02:12 pm
Partner Headlines for SYN
